Paper37242533
Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels-Potent Clinical Implications.
Koutsogianni AD and 4 others. Pharmaceuticals (Basel), 2023. Cited by 22 papers, by iCite.
Cite this record
ConductScience Library. Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels-Potent Clinical Implications. Papers, record 37242533. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37242533
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels-Potent Clinical Implications.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Athens, July 6, 2021, Protocol Number 514 Φ/4 | Hellenic Atherosclerosis Society | PubMed |
Source PubMed
References109
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36764050 | Trends and consequences of lipoprotein(a) testing: Cross-sectional and longitudinal health insurance claims database analyses. | Atherosclerosis | 2023 | https://conductscience.org/library/papers/36764050 | PubMed |
| 2 | 32187462 | Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32187462 | PubMed |
| 3 | 25014686 | Effects of extended-release niacin with laropiprant in high-risk patients. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25014686 | PubMed |
| 4 | 28454801 | Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. | Am Heart J | 2017 | https://conductscience.org/library/papers/28454801 | PubMed |
| 5 | 30293769 | Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. | Lancet | 2018 | https://conductscience.org/library/papers/30293769 | PubMed |
| 6 | 34172394 | Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial. | J Clin Lipidol | 2021 | https://conductscience.org/library/papers/34172394 | PubMed |
| 7 | 24754313 | Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver-selective thyroid hormone receptor agonist eprotirome. | J Intern Med | 2015 | https://conductscience.org/library/papers/24754313 | PubMed |
| 8 | 22516069 | Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis. | Arterioscler Thromb Vasc Biol | 2012 | https://conductscience.org/library/papers/22516069 | PubMed |
| 9 | 27206939 | Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. | J Clin Lipidol | 2016 | https://conductscience.org/library/papers/27206939 | PubMed |
| 10 | 24161338 | Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. | J Am Coll Cardiol | 2014 | https://conductscience.org/library/papers/24161338 | PubMed |
| 11 | 30561610 | Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment. | Eur Heart J | 2019 | https://conductscience.org/library/papers/30561610 | PubMed |
| 12 | 31130489 | Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy. | J Clin Lipidol | 2019 | https://conductscience.org/library/papers/31130489 | PubMed |
| 13 | 25614280 | Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. | Arterioscler Thromb Vasc Biol | 2015 | https://conductscience.org/library/papers/25614280 | PubMed |
| 14 | 25490294 | [Long-term follow-up in patients with homozygous familial hypercholesterolemia; 13-year experience of a university hospital lipid clinic]. | Turk Kardiyol Dern Ars | 2014 | https://conductscience.org/library/papers/25490294 | PubMed |
| 15 | 35163026 | Development of Thyroid Hormones and Synthetic Thyromimetics in Non-Alcoholic Fatty Liver Disease. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35163026 | PubMed |
| 16 | 29071331 | Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. | JAMA Cardiol | 2018 | https://conductscience.org/library/papers/29071331 | PubMed |
| 17 | 10336452 | Estrogen modulation of apolipoprotein(a) expression. Identification of a regulatory element. | J Biol Chem | 1999 | https://conductscience.org/library/papers/10336452 | PubMed |
| 18 | 18775538 | Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. | Atherosclerosis | 2009 | https://conductscience.org/library/papers/18775538 | PubMed |
| 19 | 25014706 | Safety profile of extended-release niacin in the AIM-HIGH trial. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25014706 | PubMed |
| 20 | 7679504 | 5' control regions of the apolipoprotein(a) gene and members of the related plasminogen gene family. | Proc Natl Acad Sci U S A | 1993 | https://conductscience.org/library/papers/7679504 | PubMed |
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42643372 | Lipoprotein(a) in cardiovascular disease: pathophysiology, residual risk, and emerging therapeutic strategies. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42643372 | PubMed |
| 42553348 | Lipoprotein (a) and inflammatory bowel disease: a systematic review and meta-analysis. | Ann Gastroenterol | 2026 | https://conductscience.org/library/papers/42553348 | PubMed |
| 42152281 | Zerlasiran for Lipoprotein(a) Reduction: Mechanisms, Evidence, and Future Directions. | Cardiovasc Hematol Disord Drug Targets | 2026 | https://conductscience.org/library/papers/42152281 | PubMed |
| 41612460 | Hepatic targeting in ASCVD: integrating lipid lowering and inflammation modulation from statins to gene editing. | J Transl Med | 2026 | https://conductscience.org/library/papers/41612460 | PubMed |
| 40944095 | Ethnic Variation in Lipoprotein(a) Levels in the Kazakhstan Population. | J Clin Med | 2025 | https://conductscience.org/library/papers/40944095 | PubMed |
| 40083956 | Valvular calcification in chronic kidney disease: new insights from recent clinical and preclinical studies. | Clin Kidney J | 2025 | https://conductscience.org/library/papers/40083956 | PubMed |
| 39867207 | Statins-Their Effect on Lipoprotein(a) Levels. | Rev Cardiovasc Med | 2025 | https://conductscience.org/library/papers/39867207 | PubMed |
| 39855644 | Lipid-lowering and antihypertensive drugs on aortic disease risk: insights from Mendelian randomization analysis and real-world pharmacovigilance data. | Eur Heart J Cardiovasc Pharmacother | 2025 | https://conductscience.org/library/papers/39855644 | PubMed |
| 39781530 | Lipoprotein(a) and Atrial Fibrillation: Mechanistic Insights and Therapeutic Approaches. | Int J Med Sci | 2025 | https://conductscience.org/library/papers/39781530 | PubMed |
| 39776103 | The impact of tamoxifen on apolipoproteins and lipoprotein(a) levels: an updated meta-analysis of randomized controlled trials. | Endocrine | 2025 | https://conductscience.org/library/papers/39776103 | PubMed |
| 38927436 | The Role of Lipoprotein(a) in Peripheral Artery Disease. | Biomedicines | 2024 | https://conductscience.org/library/papers/38927436 | PubMed |
| 38542510 | Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand? | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38542510 | PubMed |
| 38535096 | Neutrophil Extracellular Traps (NETs) and Atherosclerosis: Does Hypolipidemic Treatment Have an Effect? | J Cardiovasc Dev Dis | 2024 | https://conductscience.org/library/papers/38535096 | PubMed |
| 37887316 | Lipoprotein(a)-60 Years Later-What Do We Know? | Cells | 2023 | https://conductscience.org/library/papers/37887316 | PubMed |
| 37668953 | Treatment of Lp(a): Is It the Future or Are We Ready Today? | Curr Atheroscler Rep | 2023 | https://conductscience.org/library/papers/37668953 | PubMed |
| 37371756 | Evidence and Uncertainties on Lipoprotein(a) as a Marker of Cardiovascular Health Risk in Children and Adolescents. | Biomedicines | 2023 | https://conductscience.org/library/papers/37371756 | PubMed |
Genes13
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37242533
GET https://conductscience.org/api/papers/v1/37242533/references?page=2